NCT02051244 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Kesler A, Vakhapova V, Korczyn AD, Naftaliev E, Neudorfer M
Retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Clin Neurol Neurosurg. 2011 Sep;113(7):523-6. doi: 10.1016/j.clineuro.2011.02.014. Epub 2011 Mar 31.
Lu Y, Li Z, Zhang X, Ming B, Jia J, Wang R, Ma D
Retinal nerve fiber layer structure abnormalities in early Alzheimer's disease: evidence in optical coherence tomography. Neurosci Lett. 2010 Aug 9;480(1):69-72. doi: 10.1016/j.neulet.2010.06.006. Epub 2010 Jun 8.
Paquet C, Boissonnot M, Roger F, Dighiero P, Gil R, Hugon J
Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett. 2007 Jun 13;420(2):97-9. Epub 2007 Mar 19.

Pilot Study That Investigates the Potential of Using OCT (Optical Coherence Tomography) Measurements of the Thickness of the Retinal Nerve Fiber Layer as a Biomarker for the Early Detection of Alzheimer's Disease.

Details for clinical trial NCT02051244

Clinical trial NCT02051244 - References